according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone Ointment Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : ointment

Colour: white to off-whiteOdour: No data available

Suspected of damaging the unborn child. Toxic to aquatic life with long lasting effects.

GHS Classification

Reproductive toxicity : Category 2

Long-term (chronic) aquatic

hazard

Category 2

GHS label elements

Hazard pictograms



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

H411 Toxic to aquatic life with long lasting effects.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Suspected of damaging the unborn child.

Environmental hazards

Toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	>= 70 -< 90
2-Methyl-2,4-pentanediol	107-41-5	>= 10 -< 20
Propylene glycol monostearate	1323-39-3	>= 1 -< 10
Mometasone	83919-23-7	>= 0.1 -< 0.25

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 2024/04/06 1751211-00015 Date of first issue: 2017/06/14 3.2

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. Suspected of damaging the unborn child.

Most important symptoms and effects, both acute and

delayed

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Water spray Suitable extinguishing media

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Inhal- able particu-	5 mg/m3	ACGIH

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

		late matter)			
2-Methyl-2,4-pentanediol	107-41-5	MAC	100 mg/m3	CN OEL	
		TWA (Va-	25 ppm	ACGIH	
		pour)			
		STEL (Va-	50 ppm	ACGIH	
		pour)			
		STEL (Inhal-	10 mg/m3	ACGIH	
		able fraction,			
		Aerosol only)			
Propylene glycol monostearate	1323-39-3	TWA (Inhal-	10 mg/m3	ACGIH	
		able particu-			
		late matter)			
		TWA (Res-	3 mg/m3	ACGIH	
		pirable par-			
		ticulate mat-			
		ter)			
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal	
	Further information: Skin				
		Wipe limit	10 μg/100 cm ²	Internal	

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from

stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.
Combined particulates and organic vapour type

Filter type : Combined particulates and organic vapour type Eye/face protection : Wear safety glasses with side shields or goggles.

. Wear said by glasses with said sinces of goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : ointment

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : > 93.3 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Vapours may form explosive mixture with air. Can react with strong oxidizing agents.

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : Oxidizing age

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Components:

Petrolatum:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 420

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Propylene glycol monostearate:

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:

Petrolatum:

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

2-Methyl-2,4-pentanediol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Propylene glycol monostearate:

Result : No skin irritation

Mometasone:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Petrolatum:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

2-Methyl-2,4-pentanediol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Mometasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Components:

Petrolatum:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

2-Methyl-2,4-pentanediol:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

Components:

Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Petrolatum:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Petrolatum:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Skin contact

Result: negative

Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion
Method: OECD Test Guideline 443

Result: negative

Effects on foetal develop-

ment

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 443

Result: positive

Reproductive toxicity - As-

sessment

: Some evidence of adverse effects on development, based on

animal experiments.

Mometasone:

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 2024/04/06 1751211-00015 Date of first issue: 2017/06/14 3.2

Effects on fertility Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight

Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on

sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks Based on available data, the classification criteria are not met.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

STOT - repeated exposure

Not classified based on available information.

Components:

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Petrolatum:

Species : Rat

NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

2-Methyl-2,4-pentanediol:

Species : Rat

NOAEL : >= 450 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Method : OECD Test Guideline 408

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Experience with human exposure

Components:

2-Methyl-2,4-pentanediol:

Eye contact : Target Organs: Eyes

Symptoms: Irritation

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Petrolatum:

Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10,000 mg/l

Exposure time: 48 h

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

NOEL (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 10 mg/l

Exposure time: 21 d

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Raphidocelis subcapitata (freshwater green alga)): >

429 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC10 (Raphidocelis subcapitata (freshwater green alga)): >

429 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 25 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : NOEC (Bacteria): 200 mg/l

Exposure time: 10 d

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 2024/04/06 1751211-00015 Date of first issue: 2017/06/14 3.2

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.00014

mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.34 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

Toxicity to microorganisms

100

EC50: > 1,000 mg/lExposure time: 3 h

Test Type: Respiration inhibition

Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Persistence and degradability

Components:

Petrolatum:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 31 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Biodegradability : Result: Readily biodegradable.

Biodegradation: 81 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

2-Methyl-2,4-pentanediol:

Partition coefficient: n- : log Pow: < 4

octanol/water Remarks: Calculation

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

Mobility in soil

Components:

Mometasone:

Distribution among environ-

mental compartments

: log Koc: 4.02

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Mometasone)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen- : 956

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/04/06

Further information

Sources of key data used to compile the Safety Data

Sheet

 Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CN OEL : Occupational exposure limits for hazardous agents in the

workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average ACGIH / STEL : Short-term exposure limit

CN OEL / MAC : Maximum allowable concentration

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

according to GB/T 16483 and GB/T 17519



Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.2 2024/04/06 1751211-00015 Date of first issue: 2017/06/14

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods: TECI - Thailand Existing Chemicals Inventory: TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN